Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorShanghai Hansoh Biomedical Co., Ltd
About this trial
This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).
Eligibility criteria
Qualifiers
Men or women aged more than or equal to (≥) 18 years.
Pathologically diagnosed as ES-SCLC.
Without disease progression after receiving first-line standard induction therapy (Platinum + Etoposide +PD- (L) 1 inhibitor combination therapy).
Eastern Cooperative Oncology Group (ECOG) performance status: 0~1.
Disqualifiers
Uncontrolled pleural effusion or ascites or pericardial effusion.
Known and untreated, or active central nervous system metastases.
Active autoimmune diseases or active infectious disease
Known to have interstitial pneumonia or immune pneumonia
Trial design
Treatments tested in this trial
- HS-20093 in combination with Adebrelimab
Treatment groups
50 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov